## McDermott Will&Emery

JAN 1 1 2007

Boston Brussels Chicago Düsseldorf London Los Angeles Miami Milan Munich New York Orange County Rome San Diego Silicon Valley Washington, D.C.

**FACSIMILE** 

Date:

January 11, 2007

Time Sent:

To:

Company:

Facsimile No:

Telephone No:

Mail Stop: AMENDMENT

**USPTO** 

571-273-8300

From:

Atabak R. Royaee

Direct Phone:

617,535,4108

E-Mail:

aroyaee@mwe.com

Sent By:

Direct Phone:

Client/Matter/Tkpr:

068911-0126

Original to Follow by Mail

No

Number of Pages, Including Cover:

13

Message:

BST99 1525996-1.068911.0060

The information contained in this facsimile message is legally privileged and confidential information intended only for the use of the individual or entity named above. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, or copy of this facsimile is strictly prohibited. If you have received this facsimile in error, please notify us immediately by telephone and return the original message to us at the below address by mail. Thank you.

IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL AS SOON AS POSSIBLE.

Main Facsimile: 617.535,3800

Facsimile Operator: 617.535.4000

U.S. practice conducted through McDermott Will & Emery 28 State Street

Boston, Massachusetts 02109-1775

Telephone: 817.535.4000

PAGE 1/13 \* RCVD AT 1/11/2007 2:25:10 PM [Eastern Standard Time] \* SVR:USPTO-EFXRF-5/5 \* DNIS:2738300 \* CSID:617 535 3869 \* DURATION (mm-ss):03-32

# RECEIVED CENTRAL FAX CENTER

JAN 1 1 2007

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Babish, et al.

Application No.:

10/557,293

Filing Date:

November 18, 2005

**Docket Number:** Title:

068911-0126

ANTI- INFLAMMATORY PHARMACEUTICAL COMPOSITIONS FOR

REDUCING INFLAMMATION AND THE TREATMENT OR PREVENTION OF GASTRIC TOXICITY

Examiner:

Not yet assigned

Art Unit:

Not yet assigned

## CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to Mail Stop: Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, or facsimile transmitted (571-273-8300) to the USPTO, on the date indicated below.

Date:

January 11, 2007

Jacqueline Andreu

#### MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## TRANSMITTAL LETTER

Sir.

Enclosed herewith for filing in connection with the above-identified patent application are the following:

1) Preliminary Amendment (11 pages)

There are no fees due with the filing of this Preliminary Amendment. However, the Commissioner is authorized to charge any further fees which may become due and/or credit any overpayment to Deposit Account Number 50-1133.

Respectfully submitted,

McDERMOTT WILL & EMERY LLP

Dated: January 11, 2007

Atabak R. Royaee, Reg. No. 59,037 Simona Levi-Minzi, Reg. No.: 43,750 McDERMOTT WILL & EMERY LLP

28 State Street

Boston, Massachusetts 02109 Telephone: (617) 535-4049 Facsimile: (617) 535-3800

BST99 1527721-1.068911.0126

RECEIVED
CENTRAL FAX CENTER

JAN 1 1 2007

PATENT

Attomey Docket No. 068911-0126

Group Art Unit: Not Yet Assigned

**Examiner: Not Yet Assigned** 

Confirmation No.: N/A

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

J. Babish, et al.

Application No.: 10/557,293

Filed: November 18, 2005

International Filing Date: May 21, 2004

For: Anti-Inflammatory Pharmaceutical

Compositions for Reducing

Inflammation and The Treatment or

**Prevention of Gastric Toxicity** 

### CERTIFICATE OF MAILING OR TRANSMISSION

hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or facsimile transmitted (571-273-8300) to the USPTO, on the date indicated below.

Date: January 11, 2007

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## PRELIMINARY AMENDMENT

Prior to the examination of the above application, please amend this application as follows:

Amendments to the Specification are included in this paper at page 2.

Amendments to the Claims are reflected in the listing of claims in this paper at page 3.

Remarks/Arguments follow the amendment sections of this paper at page11.